ANA Therapeutics
Founded in response to the COVID-19 pandemic, we’re investigating niclosamide as a treatment for COVID-19.
Launch date
Employees
Market cap
-
Enterprise valuation
€18—27m (Dealroom.co estimates Aug 2020.)
San Mateo California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Convertible | |
$5.0m | Seed | ||
* | N/A | Acquisition | |
| Total Funding | €4.5m | ||
Recent News about ANA Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.